Abstract: Mucinous cystic neoplasm (MCN) of pancreas is one of the precursor lesions of pancreatic ductal adenocarcinoma. The 5-year disease-specific survival for noninvasive MCNs was 100% and 20% to 60% for those with pancreatic ductal adenocarcinoma arising in a MCN. However, the significance of T1a ( ≤ 0.5 cm) and T1b ( > 0.5 and <1.0 cm) carcinoma arising in MCN as defined by the upcoming American Joint Committee on Cancer, eighth edition is unclear. In this study, we examined 3 cases of MCN with T1a or T1b carcinoma and compared their clinicopathologic characteristics and survival to 46 cases of MCN with low-grade dysplasia (MCN-LGD), 7 cases of MCN with high-grade dysplasia (MCN-HGD), and 7 cases of MCN with advanced invasive carcinoma (T2 or higher T stage). The tumors from all 3 cases were submitted in their entirety in 123, 296, and 200 blocks, respectively. All 3 patients were alive with no recurrence during the follow-up of 20.0, 113.8, and 137.2 months, respectively. Similarly, none of the patients who had MCN with either LGD or HGD had recurrence or died of disease. In contrast, 5 of 7 patients who had MCN with advanced invasive carcinoma had recurrence and later died of disease with a median survival of 22.9 months (P < 0.001). Our study showed that MCN with T1a and T1b carcinoma had an excellent prognosis similar to MCNs with LGD or HGD after complete tumor sampling for histologic examination. Our results along with the previous studies suggest that close follow-up, rather than aggressive systemic therapy, may be a better approach for these patients.
M ucinous cystic neoplasm (MCN) is a rare cystic, mucin-producing neoplasm of the pancreas. In 1978, Compagno and Oertel 1 first proposed to separate cystic, mucin-producing pancreatic neoplasm from serous cystic neoplasm of the pancreas. In 1996, the World Health Organization (WHO) classified cystic, mucin-producing pancreatic neoplasm into mucinous cystic tumor and intraductal papillary mucinous tumor, which were later renamed as MCN and intraductal papillary mucinous neoplasm (IPMN) in the 2000 WHO Classification. 2 Along with IPMN and pancreatic intraepithelial neoplasia, MCN is now considered one of the well-established precursor lesions of pancreatic ductal adenocarcinoma (PDAC). 3 In contrast to IPMN and pancreatic intraepithelial neoplasia, which may be multifocal, MCN is almost always solitary, with the majority located in the body and tail of the pancreas. MCN is characterized by the presence of ovarian-type stroma, and does not communicate with the pancreatic ductal system. The mean age at presentation is 44 years for patients with a noninvasive MCN and 55 years for patients with an MCN with associated PDAC. 4 A review of the literature shows that for patients who underwent surgical resection for MCN, the reported frequency of invasive PDAC arising in association with MCN ranges from 3.9% to 36%. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] Because of the malignant potential of MCN, the current guidelines recommend resection of MCN, irrespective of lesion size. 5, 6 Complete surgical resection of a noninvasive MCN is curative with a 5-year disease-specific survival rate of 100%. 10, 13 However, the 5-year disease-specific survival rate is 20% to 60% for patients of MCN with advanced invasive carcinoma (MCN-AIC). 4, 5, 9, 10, 12, 14, 15 Recently, it has been reported that minimally invasive carcinoma (< 0.5 cm) 11, 12 as well as invasive carcinomas arising from MCN with invasion limited to ovarian-like stroma or intratumoral septa, have a good prognosis. 10, 15, 16 In the new upcoming eighth American Joint Committee on Cancer (AJCC) staging system for pancreatic cancer, T1 tumor is subclassified into: T1a, invasive carcinoma ≤ 0.5 cm; T1b, invasive carcinoma > 0.5 and <1.0 cm; and T1c, invasive carcinoma size of 1 to 2 cm. 17 However, the prognostic significance of the newly defined pancreatic T1a and T1b carcinoma arising from a MCN is unclear. Here 
MATERIALS AND METHODS

Study Population and Patient Follow-up
This study was approved by the Institutional Review Board. Sixty-three MCN patients with or without an associated PDAC, who underwent surgical resection with curative intent from January 1, 1991 to June 30, 2016 were identified from a database that is prospectively maintained by the Department of Surgical Oncology and the pathology database in the Department of Pathology at the University of Texas MD Anderson Cancer Center. There were 3 male and 60 female patients with a mean age of 53.6 years (range, 21.8 to 79.4 y) at the time of surgery. Radiologic features of patients diagnosed with MCN with T1a or T1b carcinoma are reviewed by a radiologist (E.P.T.). The clinical and follow-up information, such as patient age, sex, date of diagnosis, tumor site, type of surgery, prior or concurrent lesions in other sites/organs, date, and site(s) of recurrence was verified by reviewing patients' medical records. The date and cause of death when applicable was determined by the documented clinical follow-up information and the US Social Security Index. The duration of follow-up ranged from 1 to 196 months (mean, 49.1 mo). Two cases of MCN with T1a or T1b carcinoma in this study were included in Lewis study (cases 1 and 2 corresponding to cases 11 and 10, respectively). 16 In current study, however, we provided much more detailed clinical, radiographic, and pathologic characterization of both cases. In addition, we have followed both patients for additional > 5 years.
Pathologic Examination of Pancreatectomy Specimens
For all cases, if no invasive carcinoma was identified after careful gross examination, the entire tumor was submitted for histologic examination according to our institutional protocol. The diagnosis of MCN was defined as a mucin-producing cystic lesion of the pancreas with distinctive ovarian stroma and no connection to the pancreatic ductal system. The cases were further stratified into MCN with lowgrade dysplasia (MCN-LGD); MCN with high-grade dysplasia (MCN-HGD); MCN with T1a or T1b carcinoma (< 1.0 cm invasion) and MCN-AIC (T2 or higher T stage) based on the WHO criteria and AJCC Cancer Stage, eighth edition. 17 There was no MCN with T1c carcinoma identified in our database. All the cases were reviewed by 2 gastrointestinal pathologists (L.H. and H.W.) who were blinded about the clinical and follow-up data.
Statistical Analysis
Statistical analysis was performed using Statistical Package for Social Sciences software for Windows (version 22; SPSS Inc., Chicago, IL). χ 2 or Fisher analyses were used to compare categorical data and analysis of variance was used to compare continuous variables. Survival curves were constructed using the Kaplan-Meier method, and the log-rank test was used to evaluate the statistical significance of differences. Overall survival was calculated from the date of diagnosis to the date of death or the date of last follow-up if death did not occur. A 2-sided significance level of 0.05 was used for all statistical analyses.
RESULTS
The clinical features of 63 MCNs are summarized in Table 1 . The tumor sizes ranged from 0.80 to 22.0 cm. Fifty-six patients underwent distal pancreatectomy and 7 patients had pancreaticoduodenectomy. The resection margins were negative in all cases. Among the 63 patients, 46 (73.0%) were MCN-LGD, 7 (11.1%) were MCN-HGD, 3 (4.8%) were MCN with T1a or T1b carcinoma, and 7 (11.1%) were MCN-AIC. There was no MCN with T1c carcinoma identified in our database. The mean ages for patients with MCN-LGD, MCN-HGD, MCN with T1a or T1b carcinoma, and MCN-AIC were 52.9 ± 14.1, 42.2 ± 10.5, 53.5 ± 8.2, and 54.3 ± 12.0 years, respectively. There were no significant differences in patient mean ages among different groups (P > 0.05). The mean tumor sizes for MCN-LGD, MCN-HGD, MCN with T1a or T1b carcinoma, and MCN-AIC were 4.8 ± 4.0, 9.7 ± 7.7, 13.0 ± 3.0, and 7.5 ± 3.5 cm, respectively. The mean tumor size of MCN-LGD was smaller than those of MCN-HGD (P = 0.01) and those with T1a or T1b carcinoma (P = 0.001). Among 7 (Table 1) . One patient of MCN-AIC had a metastasis to the right ovary (stage IV disease) at the time of surgery. All 3 patients who had MCN with T1a or T1b carcinoma had stage IA disease at the time of surgery based on the AJCC staging Manual, eighth edition. Patient #1 was a 60-year-old female, who had a long history of irritable bowel syndrome, presented with intermittent epigastric pain. She underwent abdominal ultrasound followed by computed tomographic (CT) scan. CT scan showed an 8.3×5.7 cm complex cystic mass in the tail of pancreas with irregular and enhancing internal septations, foci of calcification, and 1 internal nodule (Figs. 1A, B) . She underwent distal pancreatectomy and splenectomy. Grossly, there was a multiloculated 10.0×7.0×5.0 cm cyst tumor filled with mucinous fluid with areas of calcification in the tail of pancreas. Maximal cyst wall thickness was 1.5 cm. There was no communication with the pancreatic ducts and no solid mass lesion identified grossly. The tumor was submitted in its entirety in 123 blocks. Histopathologic examination showed a MCN with LGD, focal HGD, and 6 separate foci of poorly differentiated PDAC measuring up to 0.6 cm in size and 43 negative lymph nodes (0/43). All foci of invasive adenocarcinoma were identified in the superficial layer of the cyst wall in the ovarian stroma. There were no complex intraluminal nodules identified (Figs. 1C-F) . The pancreatic margin is negative for tumor. The patient received close follow-up with no further treatment. There was no recurrence during the follow-up of 137.2 months.
Patient #2 was a 57-year-old female who was in her usual state of health and found to have a large abdominal mass during a regular checkup. She underwent a CT scan of abdomen and pelvis with contrast, which showed a 16×15 cm cystic mass with an irregularly thickened wall, and nodular foci of mural enhancement in the tail of the pancreas (Figs. 2A, B ). There were no lesions identified in other organs and no pancreatic or biliary ductal dilatation. She underwent distal pancreatectomy, splenectomy, and celiac lymphadenectomy. Grossly, there was a large unilocular cystic tumor (16.0×16.0×14.5 cm) in the pancreas containing tan-brown clear fluid with a fibrotic wall measuring up to 2.0 cm in thickness. Along the cyst wall were 4 delicate papillary excrescences (1.5×1.5×0.3 cm up to 3.5×2.5×0.3 cm), which did not invade the cyst wall. The rest inner surface of the cyst was smooth. There was no solid mass lesion identified grossly. The tumor was submitted in its entirety in 296 blocks. Histopathologic examination showed a MCN, mostly denuded, with LGD, HGD, carcinoma in situ, and 3 foci of moderately differentiated PDAC measuring up to 0.3 cm in size invading the wall of MCN. All 3 foci of PDAC were identified in the superficial layer of hyalinized stroma of the cyst wall, not in the papillary excrescences (Fig. 3) . Twenty-eight regional lymph nodes were negative for carcinoma (0/28). The pancreatic margin is negative for tumor. The patient received close follow-up, but no further treatment. She had no recurrence during the follow-up of 113.8 months.
Patient #3 was a 44-year-old female who presented with abdominal pain, nausea, and vomiting. She underwent CT scan, which showed a 15.2×12.6 cm cystic mass in the tail of the pancreas protruding into the left retroperitoneum with internal nodule, mural calcification, and septations with enhancement/vessels (Figs. 2C, D) . She underwent distal pancreatectomy and splenectomy. Grossly, there was a well-circumscribed, cystic lesion in the tail of the pancreas (13×12×8. (Figs. 4E, F) . There was no complex intraluminal nodules. Fifty-one regional lymph nodes were negative for carcinoma (0/51). The pancreatic margin was negative for tumor. Given her young age, the patient was treated postoperatively with Gemzar for 4 months. There was no recurrence during the follow-up of 20 months.
The median follow-up period for the cases of MCN-LGD, MCN-HGD, and MCN-AIC were 52.3, 73.4, and 24.0 months, respectively. During the follow-up period, none of the patients who had MCN with either LGD or HGD had recurrence or died of disease. In comparison, 5 of 7 patients who had MCN-AIC had recurrence and died of disease with a median survival of 22.9 months (P = 0.0001) and of these 5 patients, 3 developed liver metastasis; 1 had peritoneal metastasis; and 1 had local recurrence and cervical lymph node metastasis. The Kaplan-Meier survival curves for disease-specific overall survival are shown in Figure 5 . Patients of MCNs with T1a or T1b carcinoma had a good prognosis similar to patients with MCN-LGD and MCN-HGD (P > 0.05). Compared with the other 3 MCN groups, patients who had MCN-AIC had significantly shorter survival (P < 0.001).
DISCUSSION
In this study, 11.1% of patients had invasive carcinoma arising in association with a MCN. This is in keeping with the reported 3.9% to 36% prevalence of invasive carcinoma in MCN patients. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] There is very limited reported data on the relationship between the extent of invasion and the biological behavior of MCN. Yamao et al 11 and Suzuki et al 12 reported that minimally invasive carcinomas (defined as invasive carcinoma <0.5 cm) have an excellent prognosis with a 5-year survival of 100% after surgical resection. The definition of minimally invasive carcinoma used in these studies was, however, not widely accepted by other pathologists. Other studies found that patients with early invasive carcinoma limited to ovarian-like stroma or intratumoral septa of a MCN also have an excellent prognosis. 10, 15 Recently, Lewis et al 16 examined 16 patients with minimally invasive carcinoma confined to the ovarian stroma of MCNs with a mean follow-up of 48.6 months and found that only 1 patient, whose tumor was only sampled representatively for histologic examination, recurred and died of disease in their study. However, the sizes and numbers of foci of minimally invasive carcinoma were not provided in their study. Jang and colleagues reported 17 cases of MCN with early invasion (13 with pT1a, 3 with pT1b, and 1 with pT1c disease). Interestingly, 3 patients with multifocal pT1a invasion died of disease at 13, 29, and 64 months. 18 Similar to the case who died of disease in the study published by Lewis et al, 16 the tumors of these 3 cases was not area of invasive PDAC. The tumors of all 3 patients were submitted in their entirety for histologic examination in 123, 200, and 296 blocks, respectively. In all 3 cases, the invasive carcinomas were found by histology in ovarian stroma or hyalinized stroma in the superficial layer of cyst walls or the septum of the cyst. It is interesting that 23 of 29 invasive carcinomas arising from MCNs reported by Jang et al 18 have intracystic papillary nodules of ≥ 1.0 cm. None of our cases had invasive carcinoma in the intracystic papillary nodule. During follow-up, none of our patients had recurrence or died from disease during follow-up even though 2 of our patients received no adjuvant therapy after surgery. Our results are consistent with the above-mentioned studies and showed that patients with T1a or T1b carcinoma invading into the ovarian stroma of MCN have an excellent prognosis similar to those who had a MCN with no invasive carcinoma. 16, 18 Currently, there are no guidelines for the management of patients with T1a and T1b carcinoma arising in association with a MCN. Although the number of patients examined in this study is small, our results along with those from the previously mentioned studies suggest that these patients should be followed up closely. However, aggressive adjuvant therapy, which could lead to severe side effects and unnecessary medical expense, should be avoided if the tumors have been submitted in their entirety for histologic examination. Since we did not found any T1c carcinoma in our database and only 1 case of MCN with pT1c carcinoma was reported by Jang et al, 18 it remains whether MCN patients with T1cN0M0 carcinoma would have a good prognosis similar to those MCN patients with T1aN0M0 or T1bN0M0 disease or have a clinically aggressive course similar to those with MCN-AIC. Future studies are needed to address this important question.
Although there was a report of undifferentiated carcinomas with osteoclast giant cells of the pancreas follow an aggressive course, 19 others have found that presence of undifferentiated carcinoma with osteoclast-like giant cells in PDAC patients did not make a difference in prognosis. 15, 20, 21 There is also report that 61% of undifferentiated carcinoma with osteoclast-like giant cells show prominent intraductal/ intracystic growth and had better clinical outcome. 22 In this study, we reported the first case of a T1a (0.3 cm) undifferentiated carcinomas with osteoclast-like giant cells in the septum of an MCN. There was no conventional ductal/ tubular adenocarcinoma associated with this focus of undifferentiated carcinomas with osteoclast-like giant cells. However, this patient has 2 separate foci of moderately differentiated PDAC measuring 0.3 and 0.7 cm in size. Given the young age of this patient, she received gemcitabine-based adjuvant chemotherapy and was disease free at 20 month of follow-up.
In this study, none of the 53 patients with MCN-LGD or MCN-HGD had recurrence or died from the disease after resection with a mean follow-up of 59.9 or 74.3 months, respectively. Our findings are consistent with previous studies, which showed that patients who undergo resection for noninvasive MCNs have excellent prognosis with a 5-year survival rate of 100%. 4, 6 The reported 5-year survival rates for patients who had MCN-AIC ranges from 20% to 60%. 5, 10, 14 Consistent with these studies, 5 of 7 patients in our study, who had MCN-AIC (pT2 or higher stage of invasive carcinoma) died of disease. In our study, 2 of 7 patients who had MCN-AIC were men, which could represent a referral bias in our patient population. MCN in men, although rare, does exist. 11, 12, [23] [24] [25] [26] We also noted that MCN-AIC was more likely located in the head of pancreas (4/7 patients) compared with other MCN groups. It has been reported that MCN in the head of the pancreas is more likely to have invasive PDAC than those in the tail or body of pancreas. 10 Currently, there are no reliable clinical, imaging or cystic fluid biomarkers that can accurately predict the malignant potential of a MCN. 5, 27 As demonstrated in our cases, it is almost impossible to rule out a T1a or T1b invasive carcinoma without careful examination of the entire MCN by histopathology. Notably, only MCN with LGD and HGD was identified in the initial 20 representative sections from the tumor of patient #3. All 3 foci of T1a/T1b invasive carcinoma in this case were identified in the subsequently submitted sections from the rest of the MCN. Similarly only rare microscopic foci of T1a or T1b carcinoma were identified in the 133 and 296 blocks, respectively, in the other 2 cases in our study, which could have been easily missed by representative sampling. Our study highlights the importance of complete assessment of a MCN if no invasive carcinoma is identified grossly as suggested by Wilentz et al. 10 The previously reported malignant behavior of noninvasive MCN, 7, 11, 16, 28 could have been secondary to insufficient sampling of the original tumors. 10 In addition, these studies were published before the requirement of ovarian-type stroma for the diagnosis of MCN per the WHO 2010 criteria and may contain cases that would now be classified as IPMN. One limitation of our analysis is the limited number of cases. However, since we submitted the entire specimen for microscopic examination, we would be the first one offered detailed information on true microscopic invasion of MCNs as far as we can determine.
In conclusion, our study suggests that T1a and T1b carcinoma arising in association with a MCN has an excellent prognosis similar to those with MCN-LGD or MCN-HGD. Careful histologic examination of the entire tumor is critical to identify microscopic invasion (T1a and T1b carcinoma) if no invasive carcinoma is grossly identified. Our results suggest that close follow-up rather than aggressive systemic therapy may be a better approach to manage the patients with T1a and T1b carcinoma arising in a MCN after complete sampling of the tumor.
